Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price target increased by stock analysts at Rothschild & Co Redburn from $153.00 to $159.00 in a research note issued on Tuesday,MarketScreener reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Rothschild & Co Redburn’s price target points to a potential upside of 28.60% from the stock’s current price.

Other research analysts have also issued reports about the stock. Wolfe Research reaffirmed an “outperform” rating and issued a $150.00 price target on shares of Gilead Sciences in a report on Monday, December 15th. HSBC raised their price target on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Morgan Stanley dropped their target price on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 13th. UBS Group reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, January 15th. Finally, TD Cowen increased their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $133.52.

Gilead Sciences Trading Down 0.4%

Shares of GILD opened at $123.64 on Tuesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences has a 12 month low of $91.84 and a 12 month high of $128.70. The stock’s 50-day moving average is $123.53 and its two-hundred day moving average is $118.29. The stock has a market cap of $153.40 billion, a PE ratio of 19.13, a P/E/G ratio of 0.66 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the prior year, the company posted $2.02 EPS. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the completion of the sale, the chief executive officer owned 566,698 shares of the company’s stock, valued at $70,740,911.34. This represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 136,757 shares of company stock worth $16,951,612. 0.27% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. SOA Wealth Advisors LLC. increased its holdings in Gilead Sciences by 8.7% in the 4th quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 81 shares during the period. Trivium Point Advisory LLC increased its stake in Gilead Sciences by 1.1% in the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after acquiring an additional 83 shares during the period. Binnacle Investments Inc raised its position in Gilead Sciences by 11.8% in the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 83 shares in the last quarter. Rothschild Investment LLC lifted its stake in Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after purchasing an additional 84 shares during the period. Finally, Hemington Wealth Management boosted its holdings in Gilead Sciences by 9.3% during the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 85 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.